Savior Lifetec (4167) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Savior Lifetec TWD 9.89, price TWD 19.40, upside -49.0%, quality 63 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Savior Lifetec for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Savior Lifetec Corporation engages in the research, development, design, manufacture, and sale of carbapenem generics in the Americas, Asia, Taiwan, Europe, and internationally. The company offers injection generics, controlled-release generics, the development of new dosage forms and drugs, and the APIs, excipients, intermediates, and dosage forms.
Show more
Savior Lifetec Corporation engages in the research, development, design, manufacture, and sale of carbapenem generics in the Americas, Asia, Taiwan, Europe, and internationally. The company offers injection generics, controlled-release generics, the development of new dosage forms and drugs, and the APIs, excipients, intermediates, and dosage forms. It also provides medicine manufacturer technology and services. In addition, the company sells antibacterial raw materials and injectables. Savior Lifetec Corporation was founded in 1993 and is headquartered in Tainan City, Taiwan.
Stock analysis
Savior Lifetec (4167) currently trades at 19.40 TWD, while our model-based Fair Value estimate is 9.89 TWD, implying the stock looks roughly 96.2% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 28.77 TWD per share, and 3 of the 15 models we run sit above the 19.40 TWD price.
Bear case: the Dividend Discount group reads lowest at 3.04 TWD, and 12 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: 8.35 TWD (bear) to 12.48 TWD (bull), the price of 19.40 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 63/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Savior Lifetec reported revenue of 1.2B TWD in FY2025 versus 1.7B TWD in FY2021, a compound −8.9%/yr. Reported net income was 537M TWD in FY2025.
Key figures
Market cap 6.0B TWD (≈ $189M) · P/E ratio 11.3 · P/S ratio 5.07 · EPS (TTM) 1.71 TWD · Dividend yield 4.1% · Net margin 44.7% · Return on equity 6.4% · Return on assets (EBIT) 1.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).
What moves the price
The share trades about 11% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −49%, 4167 screens richer than that median.
Fair Value models
Bear 8.35 TWDFair Value 9.89 TWDBull 12.48 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.6645 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.19/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−1.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.0%
Start year 2020 (pandemic). Over 10 years: +0.7% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +22.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+18.4%
Dividend (yield on the price)4.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 17%
⚠ Revenue per share shrinking 3.8%/yr over ~10Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
⚠ Approximate: the rate leans on 2025, which sits 1,852% above its own trend.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks
Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score63 · Top 25%
Fair Value upside−50% · Below median
Profitability
Return on equity (TTM)6% · Above median
Return on assets2% · Top 25%
Net margin (TTM)21% · Top 25%
Operating margin (TTM)8% · Above median
Growth and dividend
Revenue growth−12% · Below median
Dividend yield (TTM)4.1% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (TTM)11.3× · Cheapest 25%
P/B1.62× · Cheaper than median
P/S (TTM)5.22× · Pricier than median
EV/EBITDA21.3× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)25· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)83· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Savior Lifetec Fair Value". https://www.fairvalue-calculator.com/stock/4167
Frequently asked questions
Is Savior Lifetec (4167) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 9.89 TWD versus a price of 19.40 TWD, about −49% upside (overvalued).
What is the fair value of 4167?
Our model-based fair value for Savior Lifetec is 9.89 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 19.40 TWD.
What is the quality score of 4167?
Savior Lifetec has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Savior Lifetec (4167)?
Our model-based price target is the fair value of 9.89 TWD (as of Sep 24, 2026) from 15 valuation models. Cautious scenario 8.35 TWD, optimistic scenario 12.48 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Savior Lifetec stock forecast for 2026?
Our models put fair value at 9.89 TWD, about −49% upside versus a price of 19.40 TWD (overvalued). Cautious scenario 8.35 TWD, optimistic scenario 12.48 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Savior Lifetec (4167)?
Savior Lifetec reported trailing-twelve-month revenue of about 1.2B TWD (latest available figure, as of Sep 24, 2026).
Does Savior Lifetec pay a dividend?
Savior Lifetec currently shows a dividend yield of about 4.15% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Savior Lifetec (4167)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Savior Lifetec it is 9.89 TWD per share (as of Sep 24, 2026), against a price of 19.40 TWD. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Savior Lifetec stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 4167 trades above its calculated fair value: price 19.40 TWD, fair value 9.89 TWD, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4167?
No. The price is what the market pays today (19.40 TWD); the fair value is what the company's own numbers justify (9.89 TWD). For Savior Lifetec the two are 9.51 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Savior Lifetec worth?
The market values Savior Lifetec at about 6.0B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 19.40 TWD; our models calculate a fair value of 9.89 TWD per share.
What do the bullish and bearish scenarios say about 4167?
Our models span a range for Savior Lifetec: cautious scenario 8.35 TWD, base 9.89 TWD, optimistic 12.48 TWD per share (as of Sep 24, 2026, price 19.40 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4167?
Savior Lifetec trades at a price-to-earnings ratio of 11.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 9.89 TWD is built from several models across several years. Other multiples: P/B 1.6, P/S 5.2, EV/EBITDA 21.3.
How solid is the balance sheet of Savior Lifetec (4167)?
Balance-sheet figures for Savior Lifetec (as of Sep 24, 2026): return on equity 6.4%. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is 4167 from its 52-week high?
Savior Lifetec trades at 19.40 TWD, about 11% below its 52-week high of 21.85 TWD and 15% above the low of 16.90 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 9.89 TWD is for.
Which stocks are comparable to Savior Lifetec?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Savior Lifetec stock attractive at the current price?
The data as of Sep 24, 2026: price 19.40 TWD, calculated fair value 9.89 TWD (−49%), Quality Score 63/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4167 calculated?
We run Savior Lifetec through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 9.89 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Savior Lifetec itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Savior Lifetec (4167)?
The closing price on Sep 24, 2026 was 19.40 TWD. Our model-based fair value is 9.89 TWD, about −49% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Savior Lifetec right now?
The price sits above even our optimistic bull case (12.48 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (63/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Savior Lifetec
How large is the market capitalisation of Savior Lifetec (4167)?
The market capitalisation of Savior Lifetec is 6.0B TWD (≈ $189M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Savior Lifetec (4167)?
The price-to-sales ratio of Savior Lifetec is 5.07 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Savior Lifetec (4167)?
Earnings per share at Savior Lifetec are 1.71 TWD (price ÷ EPS = P/E 11.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Savior Lifetec (4167)?
The dividend yield of Savior Lifetec is 4.1% (payout 47.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Savior Lifetec (4167)?
The net margin of Savior Lifetec is 44.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Savior Lifetec (4167)?
The return on equity (ROE) of Savior Lifetec is 6.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Savior Lifetec (4167)?
On an EBIT basis the return on assets of Savior Lifetec is 1.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Savior Lifetec (4167)?
The operating margin of Savior Lifetec is 8.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Savior Lifetec (4167)?
Revenue at Savior Lifetec is growing −11.5% versus a year earlier (3y avg −1.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Savior Lifetec (4167)?
Earnings per share at Savior Lifetec are growing −76.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Savior Lifetec (4167) generate?
The free cash flow of Savior Lifetec is −164M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Savior Lifetec (4167) hold?
Savior Lifetec holds more cash than debt, 813M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Savior Lifetec in the live analysis
One click puts Savior Lifetec on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
